Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited - chemicals in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN L74140MH2007PLC432497 Incorporated 12 June 2007 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed Public Limited Company chemicals
Data last updated
Market Cap
₹18,286 Cr
ONESOURCE · NSE
Share Price
₹1,602.60
+0.50% today
Revenue
₹1,422 Cr
FY 2025-26 · +3.4% YoY
EBITDA
₹294 Cr
Margin 20.7%
Net Profit
−₹64.12 Cr
FY 2025-26
P/E (TTM)
0.0x
P/B 3.1x

About Onesource Specialty Pharma Limited

Data last updated: 25 September 2026

Onesource Specialty Pharma Limited is a public limited company based in Thane, Maharashtra, India. It specialises in chemical products, a part of the broader chemicals sector. Incorporated on 12 June 2007, the company has been in operation for over 19 years.

Registered with ROC Mumbai under CIN L74140MH2007PLC432497. Listed.

Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹11.46 Cr. Formerly known as Inbiopro Solutions Private Limited and Stelis Biopharma Private Limited. It is led by directors including Arun Kumar Pillai and Colin Bond Michael.

Last AGM: 22 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sector 30, Thane, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,421.59 Cr, a decline of 1.61% compared to the previous year. The net worth stands at ₹5,831.29 Cr (down 0.84% YoY). Total assets are valued at ₹7,345.79 Cr (up 7.49% YoY).

The company has a workforce of approximately 556 employees as per the latest available data. Its group structure includes 1 subsidiary.

The company is associated with 2 brands - Stelis Biopharma, Onesource. As per MCA filings, the company has open charges of ₹3,364.09 Cr and satisfied charges of ₹1,444.82 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website stelis.com.

Company Details of Onesource Specialty Pharma Limited
CIN L74140MH2007PLC432497
Registration Number 432497
Incorporation Date 12 June 2007
ROC Mumbai
Listing Status Listed
Company Status Active
Date of Last AGM 22 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Neeraj Sharma Managing Director Arun Kumar Pillai Director Colin Bond Michael Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    stelis.com
  • Social Media
  • Registered Address
    Unit No. 902 Cyber One, Plot No – 4 & 6 Sector 30A Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
  • Industry
    Chemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
Company report
Onesource Specialty Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Onesource Specialty Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Onesource Specialty Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has undergone 2 name changes throughout its history. The company was previously known as Inbiopro Solutions Private Limited, and Stelis Biopharma Private Limited. The current legal name is Onesource Specialty Pharma Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Onesource Specialty Pharma Limited Current
Inbiopro Solutions Private Limited Previous
Stelis Biopharma Private Limited Previous

CIN History of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74140MH2007PLC432497, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74140MH2007PLC432497 Current
U74140KA2007PLC043095 Previous
U74140KA2007PTC043095 Previous

Associated Brands with Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited operates two associated brands: Stelis Biopharma and OneSource. These brands represent Onesource Specialty Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Stelis Biopharma
Offers contract development and manufacturing for drug products globally. stelis.com
OneSource
Pharmaceutical contract development and manufacturing services are offered by OneSource. onesourcecdmo.com

Competitors & Alternatives of Onesource Specialty Pharma Limited

Brands and companies operating in the same space as Onesource Specialty Pharma Limited include KBI Biopharma, Aldevron, Nephron Pharmaceuticals and 7 more.

Competitor Description Location Founded
KBI Biopharma KBI Biopharma Provider of protein formulation, process & cell line development, and cGMP services Durham, United States, United States 1996
Aldevron Aldevron Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications Fargo, United States, United States 1998
Nephron Pharmaceuticals Nephron Pharmaceuticals Sterile pharmaceutical products are manufactured and contract services are provided. Florida, Puerto Rico, United States 1937
Ovagen Ovagen Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services Mayo, Ireland, Ireland 2000
Suanfarma Suanfarma Generics, nutraceuticals, and APIs are developed by Suanfarma. Madrid, Spain, Spain 1993
Enzene Biosciences Enzene Biosciences Company specializing in development of Biosimilars Pune, India, India 2006
Laurus Bio Laurus Bio Precision fermentation services for biopharma and food are provided. Bengaluru, India, India 2005
Quotient Sciences Quotient Sciences APIs and finished dosage forms are developed and manufactured. Nottingham, United Kingdom, United Kingdom 1990
Hybio Pharmaceutical Hybio Pharmaceutical Polypeptide drugs and APIs are developed and manufactured. Shenzhen, China, China 1998
Cytovance Cytovance Therapeutic proteins and antibodies are manufactured via contract biopharmaceutical services. Oklahoma City, United States, United States 2003

Business Activity of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Onesource Specialty Pharma Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited is audited by Deloitte Haskins & Sells for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Deloitte Haskins & Sells Locked Locked Locked
Premium access

Complete auditor history for Onesource Specialty Pharma Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited is currently managed by 8 directors, with 34 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Arun Kumar Pillai
Also directs: Chayadeep Ventures Llp, Agnus Capital Llp, Karuna Group Llp and 3 more
Director 07 Apr 2021 5 Years 5 Months Current
Colin Bond Michael
Also directs: Onesource Specialty Pharma Limited
Director 23 Jun 2025 1 Years 3 Months Current
Debarati Sen
Also directs: Onesource Specialty Pharma Limited
Director 27 Feb 2025 1 Years 6 Months Current
Claudio Dr Albrecht
Also directs: Onesource Specialty Pharma Limited, Dr.Reddy's Laboratories Ltd
Director 27 Feb 2025 1 Years 6 Months Current
Vijay Paul Karwal
Also directs: Onesource Specialty Pharma Limited
Director 27 Feb 2025 1 Years 6 Months Current
Bharat Dhirajlal Shah
Also directs: Onesource Specialty Pharma Limited, Salisbury Investments Private Limited, Credila Financial Services Limited
Director 26 Jul 2024 2 Years 2 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Onesource Specialty Pharma Limited FY 2025-26 filings available

Onesource Specialty Pharma Limited reported revenue of ₹1,421.59 Cr (down 1.61% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,422 Cr
-1.6% YoY
EBITDA
₹294 Cr
-17.1% YoY
Profit After Tax
−₹64.12 Cr
-161.1% YoY
Net Worth
₹5,831 Cr
-0.8% YoY
Total Assets
₹7,346 Cr
+7.5% YoY
Total Debt
₹1,276 Cr
+65.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,4221,44517238.7113221.39
Revenue growth+3.4%+171.4%-44.8%+218.2%+146.7%+9997.0%
EBITDA294355(230)(689)(96.66)(71.35)
EBITDA margin+20.7%+24.6%-133.6%-1780.7%-73.2%-333.6%
Profit before tax(91.97)(67.75)(391)(800)(231)(121)
Net profit(64.12)105(269)(656)(233)(121)
Net profit margin-4.5%+7.3%-156.7%-1695.5%-176.2%-564.9%
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
Balance sheet
Total assets7,3466,8349691,6522,1911,173
Net worth5,8315,8813967851,012776
Total debt1,2767725628641,154386
Cash & bank97.5730160.3379.8317077.77
Net working capital691516(179)(133)25914.20
Cash flow
Cash from operations8.52(67.85)(107)(163)(416)(118)
Cash from investing(495)(201)511(67.72)(692)(207)
Cash from financing359412(391)1181,162381
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue449428290376327426393334
Revenue growth (YoY)+37.2%+0.5%-26.0%+12.5%+12.0%+482.4%+598.4%+891.0%
Other income3.802.134.633.045.272.896.724.40
EBITDA11991.9210.2310685.6118241.3671.47
EBITDA margin+26.5%+21.5%+3.5%+28.3%+26.2%+42.7%+10.5%+21.4%
Depreciation71.7571.8369.6469.8367.8068.4968.7768.28
Interest30.8122.5138.2333.9627.4833.4145.8245.05
Profit before tax20.28(0.29)(93.01)5.74(4.40)82.81(66.51)(37.46)
Tax(4.70)(4.89)(4.31)(4.74)(4.21)(15.69)2.354.63
Net profit24.984.60(88.70)10.48(0.19)98.50(68.86)(42.09)
EPS (₹)2.180.40(7.74)0.91(0.02)8.59(6.31)(10.13)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,4051,30017238.7113221.39
Revenue growth+8.4%+159.8%-40.8%+198.3%+145.5%+9997.0%
EBITDA264246(233)(645)(97.23)(72.04)
EBITDA margin+18.8%+19.0%-135.8%-1667.3%-73.6%-336.8%
Profit before tax21.20(22.14)(390)(799)(230)(121)
Net profit26.50131(269)(642)(230)(121)
Net profit margin+1.9%+10.1%-156.7%-1657.8%-174.0%-566.8%
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
Balance sheet
Total assets7,4746,8819711,6532,1941,176
Net worth5,9505,9203987871,016779
Total debt1,5049425718641,154386
Cash & bank89.9522860.2579.7616977.41
Net working capital649505(177)(132)26012.03
Cash flow
Cash from operations55.18(47.28)(109)(165)(420)(115)
Cash from investing(478)(300)506(65.68)(685)(210)
Cash from financing361417(384)1181,159381
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue446419290375321477337245
Revenue growth (YoY)+39.1%-12.2%-13.8%+52.9%+33.7%+552.7%+499.1%+628.0%
Other income3.793.764.623.045.263.915.914.25
Total expenses332344284274241241338230
EBITDA11474.705.7410279.87236(1.04)15.41
EBITDA margin+25.6%+17.8%+2.0%+27.1%+24.9%+49.5%-0.3%+6.3%
Depreciation36.1834.7434.5734.2133.2833.5933.9833.44
Interest30.5222.2537.9933.3127.0332.3943.9244.11
Profit before tax51.2221.47(62.20)37.1024.82174(73.03)(57.89)
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue449428290376327426393334
Revenue growth (YoY)+37.2%+0.5%-26.0%+12.5%+12.0%+482.4%+598.4%+891.0%
Other income3.802.134.633.045.272.896.724.40
EBITDA11991.9210.2310685.6118241.3671.47
EBITDA margin+26.5%+21.5%+3.5%+28.3%+26.2%+42.7%+10.5%+21.4%
Depreciation71.7571.8369.6469.8367.8068.4968.7768.28
Interest30.8122.5138.2333.9627.4833.4145.8245.05
Profit before tax20.28(0.29)(93.01)5.74(4.40)82.81(66.51)(37.46)
Tax(4.70)(4.89)(4.31)(4.74)(4.21)(15.69)2.354.63
Net profit24.984.60(88.70)10.48(0.19)98.50(68.86)(42.09)
EPS (₹)2.180.40(7.74)0.91(0.02)8.59(6.31)(10.13)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,4221,44517238.7113221.39
Revenue growth+3.4%+171.4%-44.8%+218.2%+146.7%+9997.0%
Other income15.0217.474.232.693.771.01
Total expenses1,1271,09040272822992.74
Employee cost0.0021579.3672.8060.9935.60
EBITDA294355(230)(689)(96.66)(71.35)
EBITDA margin+20.7%+24.6%-133.6%-1780.7%-73.2%-333.6%
Depreciation27927476.2965.6870.3534.40
Interest12216689.4547.5568.0315.82
Profit before tax(91.97)(67.75)(391)(800)(231)(121)
Tax(18.16)(49.79)0.000.00(0.11)0.27
Net profit(64.12)105(269)(656)(233)(121)
Net profit margin-4.5%+7.3%-156.7%-1695.5%-176.2%-564.9%
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.4611.444.014.013.041.54
Reserves & surplus5,8195,8693927811,009774
Shareholders' funds (net worth)5,8315,8813967851,012776
Minority interest0.000.000.000.000.000.00
Secured loans1,140658137433597309
Unsecured loans13611442543155776.59
Total debt1,2767725628641,154386
Total liabilities7,3466,8349691,6522,1911,173
Assets
Gross block6,7996,6441,1391,6331,391718
Net block6,0176,1188631,3611,231633
Capital work in progress529218188334490431
Investments15.6815.7919.584.500.000.00
Inventories5332651281392754.89
Sundry debtors69041755.243.8223.642.22
Cash & bank balances97.5730160.3379.8317077.77
Loans & advances19420233.797.1042.2413.83
Total current assets1,5151,18427823051198.71
Total current liabilities82466845736325284.51
Net working capital691516(179)(133)25914.20
Total assets7,3466,8349691,6522,1911,173
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16522.269.4712267.2911.28
Net cash from operating activities8.52(67.85)(107)(163)(416)(118)
Net cash from investing activities(495)(201)511(67.72)(692)(207)
Net cash from financing activities359412(391)1181,162381
Net change in cash(127)14312.79(112)54.4756.01
Closing cash97.5730160.3379.8317077.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-1.6%+740.4%+344.1%-70.7%+517.7%+9997.0%
EBITDA growth-17.1%+9998.0%+66.7%-613.1%-35.5%+9997.0%
PBT growth-35.8%+82.7%+51.1%-245.9%-91.8%+9997.0%
Net income growth-+9998.0%+59.0%-181.9%-92.7%+9997.0%
Revenue CAGR (3Y)+232.4%+122.0%+100.3%---
EBITDA CAGR (3Y)--+47.7%---
Profitability & leverage
Net income margin-5.2%-1.2%-227.5%-2066.2%-175.0%-564.9%
Return on capital employed-0.0%0.0%0.0%0.0%0.0%
Return on net worth-0.0%0.0%0.0%0.0%0.0%
Debt / equity-0.211.211.120.860.72
Long-term debt / equity-0.080.530.530.510.56
Interest cover803.88205.08-29.24-6.30-40.73-14.96
Efficiency & per share
Fixed asset turnover-0.370.120.030.130.04
Inventory turnover-7.351.290.190.948.75
Debtors turnover-6.125.822.8210.2219.18
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)0.00513.9098.68195.87333.495,029.28
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue446419290375321477337245
Revenue growth (YoY)+39.1%-12.2%-13.8%+52.9%+33.7%+552.7%+499.1%+628.0%
Other income3.793.764.623.045.263.915.914.25
Total expenses332344284274241241338230
EBITDA11474.705.7410279.87236(1.04)15.41
EBITDA margin+25.6%+17.8%+2.0%+27.1%+24.9%+49.5%-0.3%+6.3%
Depreciation36.1834.7434.5734.2133.2833.5933.9833.44
Interest30.5222.2537.9933.3127.0332.3943.9244.11
Profit before tax51.2221.47(62.20)37.1024.82174(73.03)(57.89)
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,4051,30017238.7113221.39
Revenue growth+8.4%+159.8%-40.8%+198.3%+145.5%+9997.0%
Other income15.0127.658.752.705.861.01
Total expenses1,1421,05340568422993.43
Employee cost24021579.3672.8056.9731.22
EBITDA264246(233)(645)(97.23)(72.04)
EBITDA margin+18.8%+19.0%-135.8%-1667.3%-73.6%-336.8%
Depreciation13713576.2910970.3534.40
Interest12116289.4247.5568.0215.80
Profit before tax21.20(22.14)(390)(799)(230)(121)
Tax0.00(41.46)0.000.000.000.00
Net profit26.50131(269)(642)(230)(121)
Net profit margin+1.9%+10.1%-156.7%-1657.8%-174.0%-566.8%
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.4611.444.014.013.911.54
Reserves & surplus5,9385,9093947831,012777
Shareholders' funds (net worth)5,9505,9203987871,016779
Secured loans1,1406581373831,154309
Unsecured loans3642854344810.0076.59
Total debt1,5049425718641,154386
Total liabilities7,4746,8819711,6532,1941,176
Assets
Gross block3,6973,5871,1391,6331,392718
Net block3,1983,2008631,3611,231633
Capital work in progress469206188334440382
Investments2,9312,84819.704.5151.6753.19
Inventories5332601281392634.89
Sundry debtors73544255.413.7436.602.24
Cash & bank balances89.9522860.2579.7616977.41
Loans & advances18719233.747.0543.0713.83
Total current assets1,5461,12227823051298.37
Total current liabilities89761645536125186.34
Net working capital649505(177)(132)26012.03
Total assets7,4746,8819711,6532,1941,176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash92.0922.199.4112166.9211.17
Net cash from operating activities55.18(47.28)(109)(165)(420)(115)
Net cash from investing activities(478)(300)506(65.68)(685)(210)
Net cash from financing activities361417(384)1181,159381
Net change in cash(61.37)69.9012.78(112)54.5555.76
Closing cash89.9522860.2579.7616977.41
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+8.1%+655.9%+344.1%-70.7%+517.7%+9997.0%
EBITDA growth+7.0%+9998.0%+63.8%-563.8%-35.0%+9997.0%
PBT growth+9998.0%+94.3%+51.2%-247.8%-89.5%+9997.0%
Net income growth-79.7%+9998.0%+58.0%-179.2%-89.6%+9997.0%
Revenue CAGR (3Y)+231.1%+114.3%+100.3%---
EBITDA CAGR (3Y)--+48.0%---
Profitability & leverage
Net income margin+1.5%+1.5%-227.1%-2064.4%-173.9%-566.8%
Return on capital employed+1.6%+5.2%0.0%0.0%0.0%0.0%
Return on net worth+0.3%+3.2%0.0%0.0%0.0%0.0%
Debt / equity0.210.241.211.120.860.72
Long-term debt / equity0.100.100.540.530.510.56
Interest cover95.12144.51-28.87-6.30-40.59-14.84
Efficiency & per share
Fixed asset turnover0.390.550.120.030.130.04
Inventory turnover3.546.691.290.190.998.75
Debtors turnover2.395.235.811.926.8019.01
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)519.07517.3699.191,961.88259.755,045.70
Want more history and ratios?
You're viewing the latest exchange-filed financials for Onesource Specialty Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Onesource Specialty Pharma Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 30.50%, foreign institutional investors hold 19.20%, domestic institutional investors hold 23.40%, retail and other public shareholders hold 27.00% of Onesource Specialty Pharma Limited.

Promoters: 30.50%DII (Domestic Institutional): 23.40%FII (Foreign Institutional): 19.20%Retail & Others: 27.00%
Jun 2026
QUARTER
30.50% Promoters
23.40% DII (Domestic Institutional)
19.20% FII (Foreign Institutional)
27.00% Retail & Others
Promoter holding - history
Now 30.50% · Jun 2026High 30.50% · Mar 2026Low 29.80% · Sep 2025
28%29%30%31%32%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 29.80%Dec 2025: 29.90%Mar 2026: 30.50%Jun 2026: 30.50%30.50%29.80%30.50%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters30.50%30.50%29.90%29.80%
Public69.50%69.50%70.10%70.20%

Group Structure of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Onesource Specialty Pharma Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Biolexis Private Limited U24239KA2022PTC156696 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Onesource Specialty Pharma Limited

Open charges
₹3,364.09 Cr
Satisfied charges
₹1,444.82 Cr
Breakdown by lending institutions
Others₹2,779.09 Cr
Yes Bank Limited₹275.00 Cr
Hdfc Bank Limited₹146.00 Cr
Standard Chartered Bank₹125.00 Cr
Idbi Trusteeship Services Limited₹39.00 Cr
Latest charge details
DateLenderAmountStatus
12 Jun 2026 Others ₹310.58 Cr Open
28 Jan 2026 Others ₹75 Cr Open
27 Dec 2025 Yes Bank Limited ₹100 Cr Open
15 Dec 2025 Others ₹100 Cr Open
13 Nov 2025 Others ₹1,342.49 Cr Open

Total charge records: 32 View all charges

Employees and EPFO Compliance at Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has a workforce of 556 employees as of Mar 10, 2025.

Employee count
556
Active EPFO establishments
1
Employee growth
8.17%
Premium access

Employee and EPFO history for Onesource Specialty Pharma Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Onesource Specialty Pharma Limited

Premium access

GST registrations and filing compliance for Onesource Specialty Pharma Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Onesource Specialty Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Onesource Specialty Pharma Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Onesource Specialty Pharma Limited

Premium access

MSME payment history for Onesource Specialty Pharma Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Onesource Specialty Pharma Limited

Premium access

Corporate group structure for Onesource Specialty Pharma Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Onesource Specialty Pharma Limited

Premium access

MCA filings and documents for Onesource Specialty Pharma Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Onesource Specialty Pharma Limited

Charges
12 Jun 2026
A charge with Others amounted to Rs. 310.58 Cr with Charge ID 101312776 was registered on 12 Jun 2026.
Charges
21 May 2026
A charge with Others of Rs. 1,342.49 Cr registered on 13 Nov 2025 with Charge ID 101193627 was modified on 21 May 2026.
Charges
03 May 2026
A charge registered on 27 Feb 2024 via Charge ID 100914818 with Others was fully satisfied on 03 May 2026.
Charges
28 Jan 2026
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101242244 was registered on 28 Jan 2026.
Charges
07 Jan 2026
A charge with Idbi Trusteeship Services Limited of Rs. 39.00 Cr registered on 13 May 2021 with Charge ID 100446574 was modified on 07 Jan 2026.
Charges
27 Dec 2025
A charge with Yes Bank Limited amounted to Rs. 100.00 Cr with Charge ID 101218579 was registered on 27 Dec 2025.

Recent News on Onesource Specialty Pharma Limited

Stelis reaches $35m in first series B close
26 Nov 2018 · Global Corporate Venturing
Stelis Biopharma, Oncobiologics Form Bio2Source
05 Jun 2018 · Contract Pharma

Frequently Asked Questions about Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited is an active public limited company in the chemicals sector based in Thane, Maharashtra, India. It was incorporated on 12 June 2007 (19+ years old) and is registered under CIN L74140MH2007PLC432497. The company has 556 employees.

Onesource Specialty Pharma Limited reported revenue of ₹1,421.59 Cr for FY 2025-26 (down 1.61% YoY) based on consolidated financials.

The current directors of Onesource Specialty Pharma Limited are:

The primary industry of Onesource Specialty Pharma Limited is chemicals. The company specifically operates in chemical products. The company is currently active in this sector.

Yes, Onesource Specialty Pharma Limited is a listed company.

Onesource Specialty Pharma Limited can be reached at the registered office: Unit No. 902 Cyber One, Plot No – 4 & 6 Sector 30A Vashi Navi Mumbai, Thane, Maharashtra, India – 400703, or through the website stelis.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available